TEC方案在可手术乳腺癌新辅助化疗中的应用研究_王劲.pdfVIP

DO I :10.16073/j .cnki .cj cpt.2007.03.015 2007 2 14 3 　　CH IN J CA N CE R P REV T REA T , February 2007, V o .14 　N o .3 ·2 13 · 〖临床应用研究〗 TEC 王劲, 　王本忠, 　张敬杰 安徽医科大学第 一附属医院乳腺外科, 安徽 合肥230022 Applied study of thecombinationof docetaxel, epirubicinandcyclophosphamide (TEC) as neoadjuvant chemotherapy regimen inthetreatment of operable breast cancer WANGJ in, WANGBen-zhong, ZHANGJing-j ie Department of Breast Surgery , AnhuiMedical niversity Af f iliated First Hospital, Hef ei 230022, P.R.China 【】　:评估 T EC 方案在可手术乳 [ABSTRACT]　OBJECTIVE:To eva uate the c inica efficacy and toxicity 腺癌新辅助化疗中的临床疗效和毒性 应。 of T EC compared w ith FE C as the neoadj uvant chemotherapy regimen in :68 例经活检组织学确诊的可手术乳 the treatment of operab e breast cancer (OBC).MEHTODS:Sixty-eight 腺癌患者在术前接受新辅助化疗, 设置 F EC patients w ith OBC w ere treated w ith T EC and FEC chemotherapy before 方案为对照组。T E C 组34 例:多西他赛(艾 operation.Neoadjuvant chemotherapies of TE C containing docetaxe 75 2 素)75 mg/m , 静脉滴入, d ;Epi-A DM (艾 2 2 1 mg/m (days 1), epirubicin 90 mg/m (days 1)and cyc opho sphamide 500 2 2 2 达生)90 mg/m , 静脉滴入, d ;CT X 500 1 mg/m (days 1), and FEC containing cyc ophosphamide 500 mg/m (days 2 2 2 mg/m , 静脉滴入, d 。 FE C 组34 例:CT X 1), epirubicin 90 mg/m (day s 1), 5-f uo rouraci 5